Viral Vector and Plasmid DNA Manufacturing Market| Growth, Trends, and Forecasts (2020-2025)

ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the Report
- Key Market Trends
- Competitive Landscape
- Major Players
TABLE OF CONTENTS

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

North America

Largest Market:

North America

CAGR:

18.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wide range of immune response types.

Several players, including pharmaceutical companies, research institutes, contract manufacturing organizations, and non-profit organizations, are playing a critical role in the development and production of these vectors.
A number of clinical studies are being conducted on viral vectors and plasmid DNA manufacturing, which emphasize the potential of gene therapy to address important medical needs, and have initiated a surge of investments in drug development and commercialization of these therapies.
Factors, such as technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, are primarily driving the demand for viral vector and plasmid DNA manufacturing.

Scope of the Report

As per the scope of this report, viral vectors and plasmid DNA are the products of gene therapy, which are used for the treatment of several diseases, such as Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis. Gene therapies and other therapies that require genetic modification include the introduction of therapeutic DNA/gene into a patient's body or cell. This process is accomplished by the use of vectors. Over the past few decades, various viral and non-viral vectors have been developed and standardized for this purpose. Moreover, viral vectors and plasmid DNA are known to reduce the cost of treatment and help in decreasing repeated administrations of medications

By Product Type
		Plasmid DNA
		Viral Vector
		Non-viral Vector

By Application
		Cancer
		Genetic Disorder
		Infectious Disease
		Other Diseases

Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle-East & Africa
	GCC
	South Africa
	Rest of Middle-East & Africa

South America
	Brazil
	Argentina
	Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Plasmid DNA Segment is Expected to Register Robust Growth.

A plasmid DNA is a small DNA molecule within a cell that is different from the chromosomal DNA, which can replicate independently. Plasmid DNA is currently gaining increasing importance, due to the clinical research applications in gene therapy and genetic vaccination.
The demand and therapeutic applications for plasmid DNA (pDNA) have rapidly grown and expanded. Plasmid DNA manufacturing is used for indirect and direct clinical applications. For the direct gene transfer into the human body, good manufacturing practice (GMP)-grade plasmid DNA is being required. The plasmid DNA manufacturing is invariably outsourced to the specialized manufacturers using the in-house platform processes.
For instance, in December 2019, Genopis, plasmid DNA manufacturer in San Diego, to Launch GMP Contract Manufacturing Business for plasmid DNA production. Moreover, growing R&D on cancer research owing to the rising burden, increasing demand for DNA therapeutics are expected to fuel the segment growth over the forecast period.

To understand key trends, Download Sample Report

North America Dominates the Market in Terms of Revenue Generated

Currently, North America viral vector and plasmid DNA manufacturing market is witnessing a rapid growth in the market studied, followed by Europe. The United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage. The significant incentives offer through Orphan Drugs Act (United States) and the Orphan Medicinal Products Regulations (European Union) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavour.

To understand geography trends, Download Sample Report.

Competitive Landscape

The market studied is still in its infant stage. Hence, the increasing focus is mainly on the development of innovative products. Key market players include Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc, Thermo Fisher Scientific, and Uniqure NV, among others.

Major Players

You can also purchase parts of this report. Do you want to check out a section wise price list?

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
  2. 4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development
  3. 4.2.3 Potential Applications in Novel Drug Delivery Approaches
3. 4.3 Market Restraints
  1. 4.3.1 High Cost of Gene Therapies
  2. 4.3.2 Challenges in Viral Vector Manufacturing Capacity
4. 4.4 Porter's Five Force Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Product Type
  1. 5.1.1 Plasmid DNA
  2. 5.1.2 Viral Vector
  3. 5.1.3 Non-viral Vector
2. 5.2 By Application
  1. 5.2.1 Cancer
  2. 5.2.2 Genetic Disorder
  3. 5.2.3 Infectious Disease
  4. 5.2.4 Other Diseases
3. 5.3 Geography
  1. 5.3.1 North America
    1. 5.3.1.1 United States
    2. 5.3.1.2 Canada
    3. 5.3.1.3 Mexico
  2. 5.3.2 Europe
    1. 5.3.2.1 Germany
    2. 5.3.2.2 United Kingdom
    3. 5.3.2.3 France
    4. 5.3.2.4 Italy
    5. 5.3.2.5 Spain
    6. 5.3.2.6 Rest of Europe
  3. 5.3.3 Asia-Pacific
    1. 5.3.3.1 China
    2. 5.3.3.2 Japan
    3. 5.3.3.3 India
    4. 5.3.3.4 Australia
    5. 5.3.3.5 South Korea
    6. 5.3.3.6 Rest of Asia-Pacific
  4. 5.3.4 Middle-East & Africa
    1. 5.3.4.1 GCC
    2. 5.3.4.2 South Africa
    3. 5.3.4.3 Rest of Middle-East & Africa
  5. 5.3.5 South America
    1. 5.3.5.1 Brazil
    2. 5.3.5.2 Argentina
    3. 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Brammer Bio
  2. 6.1.2 Cobra Biologics
  3. 6.1.3 Cell and Gene Therapy Catapult
  4. 6.1.4 FinVector Vision Therapies
  5. 6.1.5 Fujifilm Diosynth Biotechnologies
  6. 6.1.6 MassBiologics
  7. 6.1.7 SIRION Biotech
  8. 6.1.8 Merck KGaA Inc.
  9. 6.1.9 Thermo Fisher Scientific
  10. 6.1.10 Uniqure NV

*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments